# Nebokitug PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nebokitug

> The next catalyst for nebokitug, sponsored by Chemomab Therapeutics Ltd. (CMMB), is its topline data readout, 1H 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for nebokitug?

The next catalyst for nebokitug, sponsored by Chemomab Therapeutics Ltd. (CMMB), is its topline data readout, 1H 2028. Press release filed with the SEC (EX-99): "The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical-stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028." [Calendar and source filings](https://sec-api.dev/pdufa/nebokitug)

Source: Press release filed with the SEC (EX-99), accession 0001178913-26-004193, https://www.sec.gov/Archives/edgar/data/1534248/000117891326004193/exhibit_99-2.htm (retrieved 2026-11-12). Last confirmed 2026-08-19. Cite: https://sec-api.dev/pdufa/nebokitug#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | nebokitug |
| Codes | CM-101 |
| Sponsor | Chemomab Therapeutics Ltd. (CMMB) https://sec-api.dev/companies/cmmb/catalysts |
| Indications | rheumatoid arthritis, with topline results |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Jul 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-07-25, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001178913-25-002894): "Positive topline results from the double-blinded portion of this trial were reported in July 2024 and results from the open label part were reported in March 2025." https://www.sec.gov/Archives/edgar/data/1534248/000117891325002894/exhibit_99-2.htm
- SEC prospectus (424B) (accession 0001178913-25-002461): "Positive topline results from the double-blinded portion of this trial were reported in July 2024 and results from the open label part were reported in March 2025." https://www.sec.gov/Archives/edgar/data/1534248/000117891325002461/zk2532755.htm

### Mar 2025: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-04-04, last confirmed 2026-03-23.
- SEC Form 10-K (accession 0001178913-26-001593): "Positive topline results from the double-blinded portion of this trial were reported in July, 2024 and results from the open label part were reported in March 2025." https://www.sec.gov/Archives/edgar/data/1534248/000117891326001593/zk2634510.htm
- SEC Form 10-K (accession 0001178913-26-001593): "Positive topline results from the double-blinded and open label portions of this trial were reported in July, 2024 and March 2025, respectively." https://www.sec.gov/Archives/edgar/data/1534248/000117891326001593/zk2634510.htm
- SEC Form 10-K (accession 0001178913-25-001205): "Positive topline results from the double-blinded portion of this trial were reported in July, 2024 and results from the open label part were reported in March 2025." https://www.sec.gov/Archives/edgar/data/1534248/000117891325001205/zk2532902.htm
- SEC Form 10-K (accession 0001178913-25-001205): "Positive topline results from the double-blinded and open label portions of this trial were reported in July, 2024 and March 2025, respectively." https://www.sec.gov/Archives/edgar/data/1534248/000117891325001205/zk2532902.htm

### 1H 2028: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: rheumatoid arthritis, with topline results.
- First seen 2026-08-19, last confirmed 2026-08-19.
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004193): "The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical-stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028." https://www.sec.gov/Archives/edgar/data/1534248/000117891326004193/exhibit_99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-26-004193): "The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028." https://www.sec.gov/Archives/edgar/data/1534248/000117891326004193/exhibit_99-3.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nebokitug.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nebokitug PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nebokitug

```bibtex
@misc{secapidev_pdufa_nebokitug_20261116,
  title        = {Nebokitug PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nebokitug}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nebokitug_20261116","title":"Nebokitug PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nebokitug","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
